Indaptus Therapeutics presented interim data from its Phase 1 trial of Decoy20 at a conference, showing positive immune responses and tolerable adverse events.
AI Assistant
INDAPTUS THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.